ANNOUNCEMENT

Save $300 on MedCity CONVERGE Healthcare Innovation Summit July 9-10 in Philadelphia. Earlybird rate ends May 20.

Topic: Durata leads

St. Jude Medical CEO: When it comes to the Durata lead, facts have been very friendly to us

St. Jude Medical CEO: When it comes to the Durata lead, facts have been very friendly to us

January 23, 2013 10:14 am by | 0 Comments

On Wednesday, St. Jude Medical CEO Dan Starks fielded a couple of questions related to its Durata ICD lead on its fourth-quarter earnings call, although there were none on a ... Read more
St. Jude Medical likely to face tough questions about FDA warning letter on earnings call

St. Jude Medical likely to face tough questions about FDA warning letter on earnings call

January 18, 2013 12:39 pm by | 0 Comments

The shoe finally dropped.The U.S. Food and Drug Administration sent a warning letter to St. Jude Medical (NYSE:STJ) on Jan. 10 regarding its inadequate design validation process for the Durata ... Read more
St. Jude Medical’s $1B share buyback is move to shore stock battered over Durata worries

St. Jude Medical’s $1B share buyback is move to shore stock battered over Durata worries

November 30, 2012 12:04 pm by | 0 Comments

St. Jude Medical (NYSE:STJ) announced Thursday that its board has authorized a $1 billion share repurchase program.The move shows that the board believes that the company’s stock is undervalued, but ... Read more
Barclays remains confident in St. Jude’s Medical and Durata leads

Barclays remains confident in St. Jude’s Medical and Durata leads

August 17, 2012 3:30 pm by | 0 Comments

Barclays released a report Friday maintaining its Overweight rating of St. Jude Medical (NYSE: STJ) and $48 PT. In the report, Barclays stated, "[While] we understand the concerns around Durata, ... Read more